Insight Molecular Diagnostics
IMDX
59 hedge funds and large institutions have $43.5M invested in Insight Molecular Diagnostics in 2020 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 16 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 14
0.14% less ownership
Funds ownership: 2.46% → 2.33% (-0.14%)
11% less funds holding
Funds holding: 66 → 59 (-7)
32% less capital invested
Capital invested by funds: $63.5M → $43.5M (-$20M)
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$996K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$288K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$246K |
| 4 |
Goldman Sachs
New York
|
+$204K |
| 5 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
+$172K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Blackcrane Capital
Bellevue,
Washington
|
-$5.7M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$462K |
| 3 |
Two Sigma Investments
New York
|
-$362K |
| 4 |
MFIM
Mesirow Financial Investment Management
Chicago,
Illinois
|
-$190K |
| 5 |
Renaissance Technologies
New York
|
-$143K |
IMDX Hedge Fund Activity: Q3 2020 in Review
59 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q3 2020, worth a combined $43.5M — down 32% from $63.5M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of IMDX and 9 opened new positions — a net loss of 7 holders — while 14 trimmed existing stakes and 26 added.
The largest buyer was BlackRock, adding an estimated $996K. The largest seller was Blackcrane Capital, exiting entirely with an estimated $5.7M sold.
- 59 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q3 2020, down from 66 in Q2 2020.
- Funds reported $43.5M of Insight Molecular Diagnostics stock for Q3 2020, down 32% quarter-over-quarter.
- 9 funds opened new Insight Molecular Diagnostics positions in Q3 2020 and 16 closed out, a net change of -7 holders.
- The largest Insight Molecular Diagnostics buyer in Q3 2020 was BlackRock, an estimated $996K added.
- The largest Insight Molecular Diagnostics seller in Q3 2020 was Blackcrane Capital, an estimated $5.7M sold.
Based on aggregated 13F filings for Q3 2020.